Renal Disease

Nephrology·MeSH: Kidney Diseases

Prevalence

230.0 / 100K

Incidence

40.0 / 100K/yr

13 drugs in development·10 companies·3 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
rayaldee	REPLIGEN CORP (RGEN)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(1)

Drug	Company
MK-2060	Merck & Co., Inc. (MRK)

Phase 2(1)

Drug	Company
zaltenibart	OMEROS CORP (OMER)

Phase 1(1)

Drug	Company
Glucose-dependent Insulinotropic Polypeptide	ENANTA PHARMACEUTICALS INC (ENTA)

Preclinical(2)

Drug	Company
mirokidney	Miromatrix Medical Inc. (MIRO)
sln548	Silence Therapeutics Plc (SLN)

Phase 1/Phase 2(2)

Drug	Company
10 GE Xenokidney	UNITED THERAPEUTICS Corp (UTHR)
GGTA1 KO Thymokidney	UNITED THERAPEUTICS Corp (UTHR)

Phase 4(4)

Drug	Company
Avacopan	AMGEN INC (AMGN)
CHM intervention group	Valneva SE (VALN)
Glucose IV	ENANTA PHARMACEUTICALS INC (ENTA)
Olimel N12	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 13 drugs in development for Renal Disease across 10 companies.

There are 3 clinical trials targeting Renal Disease tracked by BioSniper.

The estimated prevalence of Renal Disease is approximately 230.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.